Back to top

zacks-consensus-estimate: Archive

Zacks Equity Research

Signet (SIG) Down 0.8% Since Last Earnings Report: Can It Rebound?

Signet (SIG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SIGNegative Net Change

Zacks Equity Research

Palo Alto (PANW) Up 25.5% Since Last Earnings Report: Can It Continue?

Palo Alto (PANW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PANWNegative Net Change SNegative Net Change

Zacks Equity Research

Victoria's Secret (VSXY) Down 1.6% Since Last Earnings Report: Can It Rebound?

Victoria's Secret (VSXY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

VSXYNegative Net Change CPRIPositive Net Change

Zacks Equity Research

PepsiCo (PEP) Reports Next Week: Wall Street Expects Earnings Growth

PepsiCo (PEP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PEPPositive Net Change

Zacks Equity Research

Wall Street Analysts Believe Daktronics (DAKT) Could Rally 54.28%: Here's is How to Trade

The consensus price target hints at a 54.3% upside potential for Daktronics (DAKT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

DAKTPositive Net Change

Zacks Equity Research

Wall Street Analysts Believe Progress Software (PRGS) Could Rally 26.84%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 26.8% in Progress Software (PRGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

PRGSNegative Net Change

Zacks Equity Research

Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 176% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

LYELPositive Net Change

Zacks Equity Research

Does CECO (CECO) Have the Potential to Rally 26.48% as Wall Street Analysts Expect?

The mean of analysts' price targets for CECO (CECO) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

CECONegative Net Change

Zacks Equity Research

Wall Street Analysts See a 36.1% Upside in BILL Holdings (BILL): Can the Stock Really Move This High?

The mean of analysts' price targets for BILL Holdings (BILL) points to a 36.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

BILLPositive Net Change

Zacks Equity Research

Alphabet (GOOGL) Boasts Earnings & Price Momentum: Should You Buy?

The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

GOOGLNegative Net Change